Sirona Biochem Receives TSX-V Conditional Approval for Acquisition of TFChem

VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 8, 2011) - Sirona Biochem Corp. (TSX VENTURE:SBM) (the "Company"), a biotechnology company specializing in therapeutics for diabetes and obesity, announced today that the TSX Venture Exchange has given conditional approval to proceed with the previously announced acquisition of TFChem S.A.S. (see press release dated August 25, 2010). TFChem is a privately held France-based drug discovery company specializing in the synthesis and stabilization of carbohydrate-based molecules. Upon completion of the acquisition, TFChem will operate as a wholly-owned subsidiary of Sirona Biochem Corp.

Completion of the acquisition will be subject to a formal signing of the acquisition documents which will take place in France and closing of the announced private placement. Sirona Biochem anticipates completion of the acquisition on or before March 31, 2011 as previously announced.

Under the acquisition agreement, Sirona Biochem will purchase from TFChem's shareholders all of TFChem's issued shares for approximately 13,000,000 common shares in the capital of Sirona at a deemed price of CDN$0.10 per share, plus €500,000, or approximately CDN$665,716, in cash for a total purchase price of €1,500,000 or approximately CDN$1,997,150. The Sirona common shares will be issued as at the closing date and will be escrowed and released over a period of six years with immediate release of 10% of the shares on the closing date and the remaining 90% released over six years in 7.5% increments every six months.

About TFChem

TFChem is a drug-discovery company which uses the fluorine atom properties to develop new glycomimetic compounds. Based in Rouen, France, TFChem aims at becoming a major developer of carbohydrate-based drugs. For more information visit www.tfchemistry.com.

About Sirona Biochem Corp.

Sirona Biochem is a biotechnology company developing diabetes and obesity therapeutics. We are applying a proprietary chemistry technique to improve the pharmaceutical properties of our products. Developed by our partner, TFChem of France, this chemistry platform technology can be applied to improve the commercial value of many different therapeutics, cosmeceuticals and biological ingredients. Sirona Biochem recently announced its plans to acquire TFChem. For more information visit www.sironabiochem.com.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.